Navigation Links
Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Date:10/27/2009

. In the pivotal clinical development program, patients treated with rilonacept reported a greater improvement in overall symptom scores than patients treated with placebo. These improvements were sustained over time with continued rilonacept treatment. Patients reported their symptoms using a validated daily diary instrument. These assessments represent a critical measure of effectiveness in a disease characterized by frequent, unpredictable symptom flares of variable severity and duration. Unlike other agents used in the treatment of CAPS, rilonacept is supported by patient-reported symptoms data using a validated assessment instrument.

Rilonacept has been developed as a once-weekly injection which can be administered at home by the patient or their care giver following appropriate training. The most commonly reported adverse reactions with rilonacept were injection-site reaction and upper respiratory tract infection. IL-1 blockade may interfere with immune response to infections and treatment should not be initiated in patients with active or chronic infections. There have been reports of serious, life-threatening infections in patients taking rilonacept. Rilonacept should be discontinued if a patient develops a serious infection.

The authorization for approval of rilonacept in the E.U. under exceptional circumstances is permissible for products for which a company can demonstrate that comprehensive data cannot be provided, for example because of the rarity of the condition. Each year, Regeneron will need to provide the EMEA with any new information that may become available for review.

About Cryopyrin-Associated Periodic Syndromes (CAPS)

Recently, medical researchers have identified and described a group of rare, inherited, auto-inflammatory disorders, known as Cryopyrin-Associated Periodic Syndromes or CAPS. Three related conditions make up the broader disease known as CAPS: Familial Cold Aut
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
2. Peripheral Artery Disease (PAD) Patent Granted to Dimera
3. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
4. Delcath Systems Granted Third Orphan Drug Designation
5. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
6. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
7. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
8. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
9. VIASPACE Granted US Patent
10. Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
11. Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014   MSC , ... patient safety, today announced the appointment of Mary ... With 28 years of experience preparing companies for ... 2013 as Executive Vice President of Corporate Development and ... performance improvement business , as well as corporate strategy ...
(Date:8/27/2014)... LOS ANGELES , Aug. 27, 2014  Lisa ... 30 years this July 4 holiday, thanks to a ... M.D., Ph.D., an internationally renowned clinician-researcher at the University ... is a 55-year-old Peoria, Ariz. ... progressively robs its victims of sight. On June 2, ...
(Date:8/27/2014)... 27, 2014 Flagship Biosciences LLC, a ... to the pharmaceutical and medical device industries, has announced ... fast growing company has consolidated its histology and tissue ... to Westminster, CO, just north of Denver. The ... W. 103rd Ave., Suite 100, Westminster, CO 80021 , ...
(Date:8/27/2014)... 27, 2014 Riviera Beach, Florida ... the creation of the Sancilio Scientific Advisory Board ... SCI’s philosophy of looking to nature for pharmaceutical ... actions are based on sound scientific data, analyses, ... Board provides a vehicle for SCI to receive ...
Breaking Biology Technology:MSC names Mary Beth Loesch President and CEO 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Flagship Biosciences Announces Relocation and Expansion 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3
... A team of Arizona State University researchers will ... aid development of the next generations of lasers and ... in sensing and imaging for an array of defense ... by an Army Research Office grant through the defense ...
... 5 Signum Biosciences, Inc. today announced the appointment of Dr. ... Officer.  Dr. Shroot replaces Dr. Gregory Stock who will continue ... , , , ... Shroot brings to Signum an outstanding track record of success in ...
... the study at the Norris Comprehensive Cancer Center of the University ... , ... Inc. (TSX: AEZ; Nasdaq: AEZS ), (the "Company"), ... announced that the National Institutes of Health ("NIH") has awarded Dr. ...
Cached Biology Technology:Looking to leap forward on laser and photodetector technologies 2Signum Biosciences Names Braham Shroot as Chief Executive Officer 2Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 2Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 3Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 4
(Date:8/27/2014)... have largely succeeded in sidelining the use of ... its potential contributions to Americans, health conditions. But ... best way to assuage the nation,s insatiable sweet ... & Engineering News (C&EN), the weekly news ... the article, Stephen Ritter, a senior correspondent at ...
(Date:8/27/2014)... associated with outcomes after the repair of peripheral ... mechanism of injury, nerve injured, injury location, defect ... repair materials. However, despite numerous studies of outcomes ... is no agreement regarding the independent predictors of ... the predictors has not been quantified. A study ...
(Date:8/27/2014)... As of seven hours ago the Happy Camp Complex ... Northern California, the July complex had consumed 35,530 as ... seventeen fires on the Happy Camp Ranger District of ... the area on August 11, 2014. All but three ... following is a list of contained fires and their ...
Breaking Biology News(10 mins):Happy Camp and July Fire Complexes in California 2
... Mich. School children who consume foods purchased in vending ... and that may be associated with being overweight, obese or ... coronary artery disease, according to research from the University of ... sold in school stores, snack bars and other related sales ...
... breakthroughs require 21st-century drug discovery tools, such as ... screening of effective, new compounds. That,s the theme ... held Sept. 11 on "Twenty-first Century Bioscience: In ... a variety of cutting-edge advances in the field ...
... 2, 2010⎯The old joke is a joke no more. In ... CBELife Sciences Education ( CBE-LSE ), the adage that ... laid to rest forever. "Bio-math" or "math-bio" is in the ... seven essays and 17 research articles on new ways to ...
Cached Biology News:Children who eat vended snack foods face chronic health problems, poor diet 2University at Buffalo symposium on in silico methods, high throughput screening 2University at Buffalo symposium on in silico methods, high throughput screening 3You say, 'bio-math,' I say, 'math-bio': Crossing science education divide 2
... ( Abpromise for all tested applications). ... conjugated to KLH derived from within residues ... 1.(Note: the amino acid sequence is proprietary)(Peptide ... Entrez GeneID: 1822 ...
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...
RAW; Collected from 8-12 week old sexually mature mice that are free of common parasites; RAW Collected from 8-12 week old sexually mature mice that are free of common parasites....
Biology Products: